Valuation: Theracryf Plc

Market Cap 6.17M 5.39M 4.96M 4.62M 8.76M 587M 8.9M 59.51M 23.13M 289M 23.16M 22.66M 995M P/E 2026 *
-1.44x
P/E 2027 * -1.76x
Enterprise Value 4.02M 3.51M 3.23M 3.01M 5.71M 383M 5.79M 38.76M 15.07M 188M 15.09M 14.76M 648M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 month-4.44%
3 months+10.26%
6 months+7.50%
Current year+7.50%
1 week 0.21
Extreme 0.21
0.22
1 month 0.21
Extreme 0.21
0.26
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.4
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap.
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/05/25Others

Director

422,727,272 19.8499%
04/03/25Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-15.69%-92.95% 6.17M
-2.14%+3.51%+74.50%+131.10% 59.1B
-0.93%+4.05%+73.64%+90.53% 55.19B
-2.29%+0.86%-13.61%-10.11% 24.67B
-0.91%+5.38%+13.84%+445.58% 24.19B
+0.64%+14.41%+44.27%-3.20% 19.69B
-2.19%+6.34%+39.72%-29.60% 17.56B
+3.58%+25.11%+196.41%+363.46% 16.22B
+4.91%+25.24%+44.61% - 14.84B
-0.55%+2.80%+26.36%+188.67% 14.04B
Average -0.01%+7.55%+48.41%+120.39% 24.55B
Weighted average by Cap. -0.67%+6.43%+58.06%+135.41%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.93M -2.69M -2.51M -4.76M -319M -4.83M -32.32M -12.56M -157M -12.58M -12.31M -540M -3.43M -3M -2.76M -2.57M -4.87M -327M -4.95M -33.08M -12.86M -161M -12.87M -12.6M -553M
Net Debt -2.15M -1.88M -1.73M -1.61M -3.06M -205M -3.1M -20.75M -8.06M -101M -8.07M -7.9M -347M 453K 396K 364K 340K 644K 43.18M 654K 4.37M 1.7M 21.22M 1.7M 1.67M 73.13M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
06/07/26 GBX 0.2150 0.00% 921,129
03/07/26 GBX 0.2150 0.00% 3,547,857
02/07/26 GBX 0.2150 0.00% 125,772
01/07/26 GBX 0.2150 0.00% 3,949,679
30/06/26 GBX 0.2150 0.00% 960,735
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002871USD
Average target price
0.0431USD
Spread / Average Target
+1,402.58%

Annual profits - Rate of surprise